Osteologix to File for EU Marketing Authorization for Osteoporosis Drug

Osteologix Inc. announced Wednesday that the company anticipates that it will be prepared to file a marketing application in 2011 in the European Union for its proprietary second-generation strontium therapy, NB S101 (strontium malonate).
RTTNews